Arch Pharmalabs expects to earn $100 million by 2010 from the bulk drug manufacturing deal it has entered into with chemicals group DSM, an official said on Tuesday.
DSM anti-infectives, part of the e9 billion-Dutch group, entered into an agreement with the company for the manufacturing of a wide variety of Active Pharmaceutical Ingredients for generic drugs including treatments for central nervous system disorders and heart ailments, Arch’s chairman & MD Ajit Kamath said.
“We will initially manufacture statins, prills and immunosupressants for DSM, but the product range may be extended going forward,” said Mr Kamath. The two companies expect to launch the first product by 2008. DSM will keep adding new molecules to its generic portfolio and adopt the technology sharing route for commercialisation.
“DSM Anti Infectives is now diversifying its portfolio of APIs to new molecules which are used in a wide range of therapeutic areas. To make this diversification quicker and to be close to the fastest-growing generic drug markets in the world, DSM has adopted the partnership route for commercialisation of its new venture into generic APIs.
The manufacturing agreement with Arch Pharmalabs will enable us to further strengthen our innovation focus in India,” said Hans Van Nistelrooij, vice-president of new business development, DSM Anti-infectives.
DSM anti-infectives, part of the e9 billion-Dutch group, entered into an agreement with the company for the manufacturing of a wide variety of Active Pharmaceutical Ingredients for generic drugs including treatments for central nervous system disorders and heart ailments, Arch’s chairman & MD Ajit Kamath said.
“We will initially manufacture statins, prills and immunosupressants for DSM, but the product range may be extended going forward,” said Mr Kamath. The two companies expect to launch the first product by 2008. DSM will keep adding new molecules to its generic portfolio and adopt the technology sharing route for commercialisation.
“DSM Anti Infectives is now diversifying its portfolio of APIs to new molecules which are used in a wide range of therapeutic areas. To make this diversification quicker and to be close to the fastest-growing generic drug markets in the world, DSM has adopted the partnership route for commercialisation of its new venture into generic APIs.
The manufacturing agreement with Arch Pharmalabs will enable us to further strengthen our innovation focus in India,” said Hans Van Nistelrooij, vice-president of new business development, DSM Anti-infectives.
No comments:
Post a Comment